The objectives of the Developmental Research Program (DRP) are to continue to renew our innovative scientific endeavors within the DF/HCC Lung Cancer SPORE and to fund efforts that will complement and enhance the overall quality of the DF/HCC Lung Cancer SPORE. The Developmental Research Program will fund both established and junior investigators as we have in the past. We will set aside $50,000 per year for the Developmental Research Program Awards from SPORE funds. The DF/HCC SPORE has an extensive track record of using institutional funds to support our Developmental Research Program. This will be supplemented with an additional $250,000 per year in institutional support as we have in the past. Three to 5 individuals will be awarded each year for as much as two years of funding. The second year of funding will be dependent on making sufficient progress on review by the Developmental Research Program. The award will facilitate the research and development of independence of basic biological science, translational science, and applied science investigators within the DF/HCC Lung Cancer SPORE program. Thus, candidates will be fellows, postdoctoral fellows, and faculty within the different training programs across the Harvard campus. Success in this Developmental Research Program Will be defined as the development of innovative translational science that will generate cancer-relevant interventions in patients with lung cancer or populations at risk for lung cancer. This program will use the infrastructure created by the Administration, Evaluation and Planning Core to: 1. Solicit applications and/or identify novel research projects in the area of lung cancer 2. Evaluate these projects for financial and core support 3. Fund innovative developmental research projects 4. Monitor progress on projects for potential transition into full project status 5. Evaluate the program's success in achieving its goals as well as overall SPORE objectives

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090578-10
Application #
8377865
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
2012-07-01
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
10
Fiscal Year
2012
Total Cost
$145,734
Indirect Cost
$70,274
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Shea, Meghan; Costa, Daniel B; Rangachari, Deepa (2016) Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis 10:113-29
Kang, Xiaozheng; Liu, Hongliang; Onaitis, Mark W et al. (2016) Polymorphisms of the centrosomal gene (FGFR1OP) and lung cancer risk: a meta-analysis of 14,463 cases and 44,188 controls. Carcinogenesis 37:280-9
Kachuri, Linda; Amos, Christopher I; McKay, James D et al. (2016) Fine mapping of chromosome 5p15.33 based on a targeted deep sequencing and high density genotyping identifies novel lung cancer susceptibility loci. Carcinogenesis 37:96-105
Kinsey, C Matthew; San Jose Estepar, Raul; Van der Velden, Jos et al. (2016) Lower Pectoralis Muscle Area is Associated with a Worse Overall Survival in Non- Small Cell Lung Cancer. Cancer Epidemiol Biomarkers Prev :
Koyama, Shohei; Akbay, Esra A; Li, Yvonne Y et al. (2016) STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res 76:999-1008
Planchard, David; Besse, Benjamin; Groen, Harry J M et al. (2016) Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 17:984-93
Patel, Yesha M; Park, Sunghim L; Han, Younghun et al. (2016) Novel Association of Genetic Markers Affecting CYP2A6 Activity and Lung Cancer Risk. Cancer Res 76:5768-5776
Nishino, Mizuki; Dahlberg, Suzanne E; Fulton, Linnea E et al. (2016) Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. Acad Radiol 23:329-36
Shea, Meghan; Huberman, Mark S; Costa, Daniel B (2016) Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma. J Thorac Oncol 11:e81-2
Sacher, Adrian G; Dahlberg, Suzanne E; Heng, Jennifer et al. (2016) Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. JAMA Oncol 2:313-20

Showing the most recent 10 out of 241 publications